Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANDOVER, Mass. , Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately.

TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations

Doximity

Inmode Ltd

The stock market can't ignore forever how quickly these businesses are growing.

3 Explosive Growth Stocks to Buy Now That Could Rocket Higher in 2023

Belite Bio Inc

Rhythm Pharmaceuticals

These three have had big-time share gains backed up by breakthrough science.

3 Breakout Growth Stocks to Buy for the Long Haul

Amazon

After a long bear market, these innovative tech stocks are poised to shoot higher in 2023.

Nasdaq Bear Market: 3 Mind-Blowing Growth Stocks You'll Regret Not Buying on the Dip

Amylyx Pharmaceuticals

Alpha Metallurgical Resources

Axsome Therapeutics

CONSOL Energy

Crescent Point Energy

Digi

Enphase Energy

First Solar

Golar LNG

International Seaways

Kellogg

Occidental Petroleum

Super Micro Computer

Semtech

Scorpio Tankers

Sierra Wireless

Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles

The year ahead for this fast-growing business is going to be an exciting one.

Here's My Top Growth Stock to Buy for 2023 and Beyond

Cardinal Health

Olink Holding AB

Silk Road Medical Inc

Neuronetics Inc

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

5 Winning Medical Product Stocks That Still Have Room to Run

ANDOVER, Mass. , Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41st Annual J.P.

TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

TransMedics Group, Inc. has a $205M in cash compared to $68M in debt and recently reported net revenue of $25.7M for Q3 22, representing a 378% increase compared to the Q3 21. OCS Kidney, the company's fourth product, is set to begin clinical trials in early 2023.

My Top Pick For 2023: TransMedics Group

Find out how these stock rockets could continue their ascent.

2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?

TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Allen Gong - J.P. Morgan Cecilia Furlong - Morgan Stanley Joshua Jennings - Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to TransMedics Third Quarter 2022 Earnings Conference Call.

TransMedics Group, Inc. (TMDX) Q3 2022 Earnings Call Transcript

TransMedics (TMDX) delivered earnings and revenue surprises of 37.50% and 35.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates

Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $ 80 million to $85 million ANDOVER, Mass. , Nov. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2022.

TransMedics Reports Third Quarter 2022 Financial Results

We advocate that TransMedics Group remains a speculative buy in the current market rout. Profitability and earnings trends continue to push north and serve as solid fundamental momentum looking ahead.

TransMedics Remains A Buy Heading Into Q3 Earnings

ANDOVER, Mass. , Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022.

TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022

TransMedics is a long-term revenue growth story in organ transplant procedures. The company's technology is seeing smooth adoption replacing the current standard of care.

TransMedics: Game Changer Technology Will Boost Revenue Growth

PROCEPT BioRobotics Corp

Sensus Healthcare

Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.

3 Resilient Medical Stocks to Watch as Rate Hikes Continue

BOSTON--(BUSINESS WIRE)--CIBC Innovation Banking is pleased to announce a new debt financing for Massachusetts-based TransMedics Group, Inc. ("TransMedics"), a market leading medical technology company that focuses on organ transplant therapy for patients with end-stage lung, heart and liver failure. TransMedics plans to use the incremental growth capital to accelerate its commercial momentum, helping to grow transplant volume and improve clinical outcomes. Founded in 1998, TransMedics was buil

CIBC Innovation Banking Provides $60 Million Debt Financing to TransMedics Group Inc.

ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York.

TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the upsize and pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $40.00 per share.

TransMedics Announces Upsize and Pricing of Public Offering of Common Stock

ANDOVER, Mass. , Aug. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $100 million of its shares of common stock.

TransMedics Announces Proposed Public Offering of Common Stock

TransMedics came in with another solid quarterly performance with upside in revenue versus consensus. The company is at an inflection point posting a record quarter in terms of sales and gross margin of 70%.

TransMedics Is A Buy Following Q2 FY22 Earnings Upside

Start Time: 16:30 January 1, 0000 5:16 PM ET TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2022 Earnings Conference Call August 01, 2022, 16:30 PM ET Company Participants Waleed Hassanein - President and CEO Stephen Gordon - CFO Brian Johnston - Gilmartin Group Conference Call Participants Bill Plovanic - Canaccord Genuity Calvin Chu - Morgan Stanley Josh Jennings - Cowen Suraj Kalia - Oppenheimer Allen Gong - JPMorgan Operator Good afternoon, and welcome to TransMedics Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2022 Results - Earnings Call Transcript

Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass. , Aug. 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022.

News for Transmedics Group Inc Stock (TMDX)